WAYNE, Pa.--(BUSINESS WIRE)--Sep. 16, 2016--
Teleflex Incorporated (NYSE: TFX), a leading provider of medical
technologies for critical care and surgery, will focus on the rise of
the vascular access specialist with its vascular access technologies and
new educational platform at the 30th Annual Scientific Meeting of the
Association for Vascular Access (AVA), in Orlando, Florida, to be held
September 16-19, 2016.
The rise of the vascular access specialist has become a part of the
mission statement for Teleflex’s Arrow® Vascular Access
business. We believe in striving for zero complications to become
reality within vascular access, and we believe that expertise in
vascular access can help achieve this goal. Teleflex supports this goal
with education, advocating scope of practice expansion and innovative
technology. At AVA this year, we will be showcasing our educational and
vascular products to support the rise of the vascular access specialist.
Teleflex will be unveiling the Teleflex Academy, a new online clinical
education platform. The booth educational experience for the Teleflex
Academy at this year’s AVA will focus on every aspect of vascular
access, inspiring confidence, enhancing skills and enabling clinicians
to make an even bigger difference in their patient’s lives. Teleflex
believes that quality education is the first step in fostering the
expansion of skills and helping to shape clinical practice.
Teleflex is excited to launch the Arrow® Midline with Chlorag+ard®
Technology, adding to the family of antithrombogenic and antimicrobial
protected catheters.1,2
The company will offer its popular Vascular Access Procedural Cadaver
Lab onsite, training on many different vascular access procedures.
Teleflex will also have clinical education activities at its booth,
where models will be used to demonstrate the full range of the company’s
vascular access devices.
At the breakfast symposium, “Rising to the Challenge: How Vascular
Access Specialists Started Placing CVCs,” attendees will be educated on
the importance of the evolution of the vascular access specialist. This
course highlights the experiences of clinicians who have made the
journey to expand their roles to place central venous catheters, and
describes the clinical process and materials needed to develop a
vascular access team.
The platinum showcase symposium, “Locking the Lumen…Consider the
Solutions!” will review why given today’s medical reimbursement risks,
facilities must explore all opportunities to reduce potential vascular
access complications. Locking solutions could provide an additional
layer of protection when used in conjunction with proven protected
catheter technology. The presentation will address catheter
colonization, intraluminal colonization and how locking solutions and
protected catheters address these.
The dinner symposium, “Strategy or Risk: the Use of Midline Catheters”,
will focus on the recent popularity of Midline catheters, the role of a
Midline, and how technology could be the key to ensuring Midline success.
“The ‘Right Line, Right Patient, Right Time™’ has been at the center of
our Vascular business model for many years and we continue to be the
market leader in this philosophy,” said Jay White, president and general
manager of the Vascular Access Division. “We have developed first class
vascular educational programs for vascular access clinicians. We are
proud to provide clinicians with solutions such as Chlorag+ard®
Technology which protects the catheter surface beyond initial insertion
in addition to tools to treat their patients with the best possible
care. We look forward to launching these clinical education and vascular
products at this year’s AVA meeting.”
About Teleflex Incorporated
Teleflex is a global provider of medical technologies designed to
improve the health and quality of people’s lives. We apply purpose
driven innovation – a relentless pursuit of identifying unmet clinical
needs – to benefit patients and healthcare providers. Our portfolio is
diverse, with solutions in the fields of vascular and interventional
access, surgical, anesthesia, cardiac care, urology, emergency medicine
and respiratory care. Teleflex employees worldwide are united in the
understanding that what we do every day makes a difference. For more
information, please visit teleflex.com.
Teleflex is the home of Arrow®, Deknatel®, Hudson
RCI®, LMA®, Pilling®, Rusch®
and Weck® – trusted brands united by a common sense of
purpose.
Forward-Looking Statements
Any statements contained in this press release that do not describe
historical facts may constitute forward-looking statements. Any
forward-looking statements contained herein are based on our
management's current beliefs and expectations, but are subject to a
number of risks, uncertainties and changes in circumstances, which may
cause actual results or company actions to differ materially from what
is expressed or implied by these statements. These risks and
uncertainties are identified and described in more detail in our filings
with the Securities and Exchange Commission, including our Annual Report
on Form 10-K.
Teleflex, the Teleflex logo, Arrow, Chlorag+ard,
Deknatel, Hudson RCI, LMA, Pilling, Right Line, Right Patient, Right
Time, Rusch and Weck are trademarks or registered trademarks of Teleflex
Incorporated or its affiliates, in the U.S. and/or other countries. All
other trademarks are trademarks of their respective owners.
©
2016 Teleflex Incorporated. All rights reserved. MC-002544
Rx Only
Contraindication:
Chlorag+ard® Technology is
contraindicated for patients with known hypersensitivity to
chlorhexidine.
References:
-
Data on file. As compared to uncoated catheters, intravascular ovine
model inoculated with Staph aureus. No correlation between in vitro
/ in vivo testing methods and clinical outcomes have currently
been ascertained.
-
In vitro data on file 2010. No correlation between in vitro
/ in vivo testing methods and clinical outcomes have currently
been ascertained.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160916005053/en/
Source: Teleflex Incorporated
Teleflex Incorporated
Jake Elguicze
Treasurer and Vice
President, Investor Relations
610-948-2836